International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 3 , Pages 648-654, 1 July 2010

Randomized Comparison of Whole Brain Radiotherapy, 20 Gy in Four Daily Fractions Versus 40 Gy in 20 Twice-Daily Fractions, for Brain Metastases

  • P.H. Graham, M.B., B.S., F.R.A.N.Z.C.R., Cert.Bioethics., G.Dip.Med.Stat.

      Affiliations

    • Cancer Care Centre, St. George Hospital, Kogarah, Australia
    • Corresponding Author InformationReprint requests to: P. H. Graham, M.B., B.S., F.R.A.N.Z.C.R., Cert.Bioethics., G.Dip.Med.Stat., Cancer Care Centre, St. George Hospital, Kogarah 2217 Australia. Tel: (+61) 2-9113-3934; Fax: (+61) 2-9113-3958
  • ,
  • J. Bucci, M.B., B.S., F.R.A.C.P., F.R.A.N.Z.C.R.

      Affiliations

    • Cancer Care Centre, St. George Hospital, Kogarah, Australia
  • ,
  • L. Browne, B.Sc., Ph.D., G.Dip.Med.Stats., M.Med.Stats., A.Stat.

      Affiliations

    • Cancer Care Centre, St. George Hospital, Kogarah, Australia

Received 10 April 2009; received in revised form 24 May 2009; accepted 26 May 2009. published online 15 October 2009.

Purpose

The present study compared the intracranial control rate and quality of life for two radiation fractionation schemes for cerebral metastases.

Methods and Materials

A total of 113 patients with a Eastern Cooperative Oncology Group performance status <3; and stable (>2 months), absent, or concurrent presentation of extracranial disease were randomized to 40 Gy in 20 twice-daily fractions (Arm A) or 20 Gy in four daily fractions (Arm B), stratified by resection status. The European Organization for Research and Treatment of Cancer Quality of Life 30-item questionnaire was administered monthly during Year 1, bimonthly during Year 2, and then every 6 months to Year 5.

Results

The patient age range was 28–83 years (mean 62). Of the 113 patients, 41 had undergone surgical resection, and 74 patients had extracranial disease (31 concurrent and 43 stable). The median survival time was 6.1 months in Arm A and 6.6 months in Arm B, and the overall 5-year survival rate was 3.5%. Intracranial progression occurred in 44% of Arm A and 64% of Arm B patients (p = .03). Salvage surgery or radiotherapy was used in 4% of Arm A patients and 21% of Arm B patients (p = .004). Death was attributed to central nervous system progression in 32% of patients in Arm A and 52% of patients in Arm B (p = .03). The toxicity was minimal, with a minor increase in short-term cutaneous reactions in Arm A. The patients’ quality of life was not impaired by the more intense treatment in Arm A.

Conclusion

Intracranial disease control was improved and the quality of life was maintained with 40 Gy in 20 twice-daily fractions. This schema should be considered for better prognosis subgroups of patients with cerebral metastases.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflict of interest: none.

PII: S0360-3016(09)00795-0

doi:10.1016/j.ijrobp.2009.05.032

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 3 , Pages 648-654, 1 July 2010